The National Heart, Lung, and Blood Institute has tapped NuGen Technologies to provide automated reagent solutions for expression profiling of approximately 6,000 blood samples from the landmark Framingham Heart Study, NuGen said this week.

NuGen's products will be used for an initiative that the Framingham Heart Study launched last year called the Systems Approach to Biomarker Research in Cardiovascular Disease, or SABRe CVD.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.